The third-generation EGFR-TKI and EGFR-TKIs + SRS/WBRT have well-known superiority for EGFR-mutant NSCLC patients with brain metastases, with acceptable safety profiles. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.